

Beta-Blockers

Selected References:

- Baard J, et al. 2020. The effect of beta-blockers on foetal birth weight in pregnancies in women with structural heart disease: a prospective cohort study. *Cardiovasc J Afr* 31(3):136-141.
- Bateman BT, et al. 2016. Late pregnancy β blocker exposure and risks of neonatal hypoglycemia and bradycardia. *Pediatrics* 138(3):e20160731.
- Davis RL, et al. 2011. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. *Pharmacoepidemiol Drug Saf* 20(2):138-45.
- Firoz T, et al. 2014. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. *BJOG* 121(10):1210-8.
- Ruys TP, et al. 2014. Cardiac medication during pregnancy, data from the ROPAC. *Int J Cardiol* 177(1):124-8.
- Semczuk M. 1987. The effects of beta-adrenergic drugs on the human sperm motility in vitro. I. The effects of propranolol and isoprenaline. *Andrologia*. 19 Spec No:256-61.
- Tanaka K. 2016. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. *Circ J*. 80(10):2221-6.
- Wu Y. (2021). Risk of congenital malformations in offspring of women using β -blockers during early pregnancy: An updated meta-analysis of observational studies. *Br J Clin Pharmacol* 87(3):806-815.
- Xie RH, et al. 2014. Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. *Eur J Obstet Gynecol Reprod Biol*. 175:124-8.
- Xie RH, et al. 2014. Beta-blockers increase the risk of being born small for gestational age or of being institutionalised during infancy. *BJOG* 121(9):1090-6.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2021.

Beta-Blockers

Selected References:

- Antonucci R, et al. 2018. Maternal carbamazepine therapy and unusual adverse effects in a breastfed infant. *Breastfeed Med* 13(2):155-157.
- Baker GA, et al. 2015. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. *Neurology* 84(4):382-90.
- Bech BH, et al. 2014. Use of antiepileptic drugs during pregnancy and risk of spontaneous abortion and stillbirth: population based cohort study. *BMJ* 349:g5159
- Blotiere PO, et al. 2020. Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study. *BMJ Open*. 7;10(6):e034829.
- Campbell E, et al. 2014. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. *J Neurol Neurosurg Psychiatry* Sep;85(9):1029-34.
- Canger R, et al. 1999. Malformations in offspring of women with epilepsy: a prospective study. *Epilepsia* 40(9):1231-1236.
- Davanzo R, et al. 2013. *Italian Journal of Pediatrics* 39:50-61.
- Deshmukh U, et al. 2016. Behavioral outcomes in children exposed prenatally to lamotrigine, valproate, or carbamazepine. *Neurotoxicol Teratol* 54:5-14.
- Fried S, et al. 2004. Malformation rates in children of women with untreated epilepsy: a meta-analysis. *Drug Saf* 27(3):197-202.
- Gaily E, et al. 2004. Normal intelligence in children with prenatal exposure to carbamazepine. *Neurology* 62:28-32.
- Gladstone DJ, et al. 1992. Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study. *Reprod Toxicol* 6:257-61.
- Harden CL. 2008. Antiepileptic drug teratogenesis: what are the risks for congenital malformations and adverse cognitive outcomes? *Int Rev Neurobiol* 83:205-13.
- Hernandez-Diaz S, et al. 2000. Folic acid antagonists during pregnancy and the risk of birth defects. *N Engl J Med* 343(22):1608-1614.
- Huber-Mollema Y, et al. 2020. Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine, or valproate exposure. *J Neurol*. 267(6):1724-1736.
- Husebye E, et al. 2020. Language impairment in children aged 5 and 8 years after antiepileptic drug exposure in tuero – the Norwegian Mother and Child Cohort Study. *European Journal of Neurology* 27.3:667-675.
- Jones KL, et al. 1989. Patterns of malformations in the children treated with carbamazepine during pregnancy. *N Engl J Med* 320(25):1661-66.
- Kallen AJB. 1994. Maternal carbamazepine and infant spina bifida. *Reprod Toxicol* 8(3):203-205.
- Meador KJ, et al. 2009. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. *N Engl J Med* 360(16):1597-1605.
- Margulis A, et al. 2019. Relation of in-utero exposure to antiepileptic drugs to pregnancy during and size at birth. *PLoS One*. Aug; 5;14(8):e0214180.
- Meador KJ, et al. 2014. Breastfeeding in children of women taking antiepileptic drugs cognitive outcomes at age 6 years. *JAMA Pediatr* Aug;168(8):729-36.
- Morrell M. 1996. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy and fetal outcome. *Epilepsia* 37(Suppl. 6):S34-S44.
- Nulman I, et al. 1997. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. *Am J Med Genet* 68:18-24.

- O'Brien MD and Gilmour-White SK. 2005. Management of epilepsy in women treated with carbamazepine during pregnancy. *Postgrad Med J* 81(955):278-285.
- Ornoy A and Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. *Arc Dis Child* 75:517-20
- Patel N, et al. 2018. Mood-stabilizing anticonvulsants, spina bifida, and folate supplementation: commentary. *J Clin Psychopharmacol* 38(1):7-10.
- Rosa FW. 1991. Spina bifida in infants of women treated with carbamazepine during pregnancy. *N Engl J Med* 324(10):674-677.
- Samren EB, et al. 1999. Antiepileptic drug regimens and major congenital abnormalities in the offspring. *Ann Neurol* 46(5):739-746.
- Scolnik D, et al. 1994. Neurodevelopment if children exposed in utero to phenytoin and carbamazepine monotherapy. *JAMA* 271(10):767-770.
- Tomson T and Barrino D. Teratogenic effects of antiepileptic drugs. *Seizure* 17(2):166-171.
- Tomson T and Klein P. 2015. Fine-tuning risk assessment with antiepileptic drug use in pregnancy. *Neurology*. 84(4):339-40.
- Tomson T, et al. 2015. Antiepileptic drugs and intrauterine death: A prospective observational study from EURAP. *Neurology* Aug 18;85(7):580-8.
- Tomson T, et al. 2018. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. *Lancet Neurol* 17(6):530-8.
- Vajda F. 2014. Epilepsy: Effects of exposure to antiepileptic drugs during development. *Nat Rev Neurol*.10:11-2.
- Vajda F, et al. 2018. Anti-epileptic drug exposure and risk of foetal death in utero. *Acta Neurol Scand* Jan;137(1):20-23.
- Wallace H, et al. 1998. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. *Lancet* 352:1970-73.
- Weston J, et al. 2016. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. *Cochrane Database Syst Rev*.11:Cd010224.
- Wide K, et al. 2000. Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. *Dev Med Child Neurol* 42:87-92.
- Wiggs K. et al. 2020. Anti-seizure medication use during pregnancy and risk of ASD and ADHD in children. *Neurology*. [Published online ahead of print October 27, 2020] Aoki FY, et al. 2013. The use of antiviral drugs for influenza: A foundation document for practitioners. *Can J Infect Dis Med Microbiol*. 24(Suppl C) :1-15.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2021.

Beta-Blockers

Selected References:

- Aporta RR, et al. 1998. Alglucerase enzyme replacement therapy used safely and effectively throughout the whole pregnancy of a Gaucher disease patient. *Haematologica*. 83:852-3.
- Amory, JK, et al. 2007. Miglustat has no apparent effect on spermatogenesis in normal men. *Human Reproduction*, **22**(3), 702-707.
- Dornelles AD, et al. 2014. Breastfeeding in Gaucher disease: is enzyme replacement therapy safe? *Clin Ther*.36:990-1.
- Elstein Y, et al. 2004. Pregnancies in Gaucher disease: a 5-year study. *Am J Obstet Gynecol*. 190(2):435-41.
- Elstein D et al. 2014. Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease. *J Obstet Gynaecol Res*.40(4):968-975.
- Gary, Sam E. et al. Recent Advances in the Diagnosis and Management of Gaucher Disease. *Expert Review of Endocrinology & Metabolism*. 13(2): 107-18
- Giannubilo SR, et al. 2015. Replacement therapy for Gaucher disease during pregnancy: A case report. *J Reprod Infertil* 16(1): 53-57.
- Granovsky-Grisaru, S et al. 2011. The management of pregnancy in Gaucher disease. *Eur J Obstet Gynecol Reprod Biol*. 156: (1) 3-8.
- Komninaka V, et al. 2020. Outcomes of pregnancies in patients with Gaucher Disease: The experience of a center of excellence on rare metabolic Disease-Gaucher Disease, in Greece. *Eur J Obstet Gynecol Reprod Biol*. 254:181-187.
- Korkmazer E, et al. 2015. Pregnancy and lactation in a patient with Gaucher disease receiving enzyme replacement therapy: Case report. *Turkey J Clin Obstet Gynecol*. 25:224-6.
- Lau H, et al. 2018. Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome survey. *Blood Cells Mol Dis*. 68:226-231.
- Mamopoulos A M et al. 2009. Gaucher disease and pregnancy. *J Obstet Gynaecol*. 29: 240-242.
- Murphy E. 2015. Pregnancy in women with inherited metabolic disease. *Obstet Med*. 8(2): 61-67.
- Paskulin L, et al. Breastfeeding in patients with Gaucher disease: Is taliglucerase alfa safe? *Molecular Genetics and Metabolism Reports*, **18**, 30-31.
- Rosenbaum H. 2015. Management of women with Gaucher disease in the reproductive age. *Thromb Res*. 135 Suppl 1:S49-51.
- Roy, A., et al. 2006. Shaping the sperm head: an ER enzyme leaves its mark. *Journal of Clinical Investigation*, 116(11), 2860-2863.
- Sekijima Y, et al. 2010. Successful pregnancy and lactation outcome in a patient with Gaucher disease receiving enzyme replacement therapy, and the subsequent distribution and excretion of Imiglucerase in human breast milk. *Clin Ther*. 32(12): 2048-2052.
- Sherer Y, et al. 2002. Successful suc outcome in a patient with Gaucher's disease and antiphospholipid syndrome. *Ann Hematol*. 81:161-3.
- Stirnemann J, et al. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. *International Journal of Molecular Sciences*, 18(2), 441.
- Weinreb, N. J. 2008. Imiglucerase and its use for the treatment of Gaucher's disease. *Expert Opinion on Pharmacotherapy*, 9(11), 1987-2000.
- Zimran A, et al. 2009. The female Gaucher patient: the impact of enzyme replacement therapy around key

reproductive events. Blood Cells Mol Dis. 43:264-288.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2021.

Beta-Blockers

Selected References:

- Berle JO, et al. 2004. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome P450 genotypes. J Clin Psychiatry 65:1228-34. PMID: 15367050
- Brunel P, et al. 1994. [Follow-up of 151 pregnant women exposed to antidepressant treatment (MAOI excluded) during organogenesis.] Therapie 49:117-122.
- Eggermont E. 1973. Withdrawal symptoms in neonate associated with maternal imipramine therapy. Lancet 2:680.
- Misri S & Sivertz K. 1991. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med 21(2):157-71.
- Mitchell JE and Popkin MK: Antidepressant drug therapy and sexual dysfunction in men: a review. J Clin Psychopharm 3:76-79, 1983.
- Nulman I, et al. 1997. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 336:258-62.
- Overo KF, et al. 1997. Interaction of perphenazine with the kinetics of nortriptyline. Acta Pharmacol Toxicol; 40:97-105.
- Shearer WT, et al. 1972. Urinary retention in a neonate secondary to maternal ingestion of nortriptyline. J Pediatr 81:570-2.
- Schoretsanitis S, et al. 2020. The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. Expert Opin Drug Metab Toxicol; 16(5):431-440.
- US Preventive Services Task Force, Curry SJ, et al. 2019. Interventions to Prevent Perinatal Depression: US

Preventive Services Task Force Recommendation Statement. JAMA 321(6):580-587.

- Webster PA. 1973. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet 2(7824):318-9.
- Weissman AM, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry 161:1066-78. PMID: 15169695
- Wisner KL, et al. 2002. Postpartum depression. N Engl J Med. 347:194-9. PMID: 12124409.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2021.

Beta-Blockers

Selected References

- Alfaraj SH, et al. 2019. Middle east respiratory syndrome coronavirus (MERS-CoV) infection during pregnancy: report of two cases & review of the literature. J Microbiol Immunol Infect 52(3):501-503.
- Alserehi H, et al. 2016. Impact of middle east respiratory syndrome coronavirus (MERS-CoV) on pregnancy and perinatal outcome. BMC Infect Dis 16:105.
- Assiri A, et al. 2016. Middle east respiratory syndrome coronavirus infection during pregnancy: a report of 5 cases from Saudi Arabia. Clin Infect Dis 1;63(7):951-3.
- Centers for Disease Control and Prevention. 2020. 2019 Novel Coronavirus: Interim Guidance for Healthcare Professionals. Available at URL: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html>. [Accessed 1/2020].
- Centers for Disease Control and Prevention. 2020. Coronavirus: Prevention and Treatment. Available at URL: <https://www.cdc.gov/coronavirus/about/prevention.html>. [Accessed 1/2020].
- Centers for Disease Control and Prevention. 2019. Coronavirus: Symptoms and Diagnosis. Available at URL: <https://www.cdc.gov/coronavirus/about/symptoms.html>. [Accessed 1/2020].
- Centers for Disease Control and Prevention. 2019. Coronavirus: Transmission. Available at URL: <https://www.cdc.gov/coronavirus/about/transmission.html>. [Accessed 1/2020].

- Jeong SY, et al. 2017. MERS-CoV infection in a pregnant woman in Korea. J Korean Med Sci 32(10):1717-1720.
- Malik A, et al. 2013. Middle east respiratory syndrome coronavirus during pregnancy, Abu Dhabi, United Arab Emirates, 2013. Emerg Infect Dis 22(3):515-7.
- Payne DC, et al. 2014. Stillbirth during infection with middle east respiratory syndrome coronavirus. J Infect Dis 15;209(12):1870-2.
- Shek CC, et al. 2003. Infants born to mothers with severe acute respiratory syndrome. Pediatrics 112(4):e254.
- Wong SF, et al. 2004. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol 191(1):292-7.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2021.